GC Cell Set to Participate in the US Cancer Moonshot Project
Initiative aims to reduce cancer mortality rates by 50% in the next 25 years.
GC Cell announced in a company press release that it will be joining CancerX, part of the US Cancer Moonshot project. Started by the Biden administration, the Cancer Moonshot aims to reduce cancer patient mortality rates by over 50% over the next 25 years. According to the company, it aims to highlight the importance and potential of cell therapy in cancer treatment through participating in the initiative.
"I am pleased to contribute to projects that can change the lives of many patients and their families,” said James Park, CEO, GC Cell.” “The Cancer Moonshot & CancerX provides an expanded opportunity to build diverse collaborative research and partnership frameworks with global companies."
Reference: GC Cell Joins US Cancer Moonshot Project. PR Newswire. October 24, 2023. Accessed October 25, 2023. https://www.prnewswire.com/news-releases/gc-cell-joins-us-cancer-moonshot-project-301966721.html
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025